Carlos Alban's most recent trade in SpringWorks Therapeutics Inc was a trade of 10,060 Common Stock done . Disclosure was reported to the exchange on May 14, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2025 | 10,060 | 28,861 (0%) | 0% | 0 | Common Stock | |
| Solventum Corp | Carlos Alban | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 3,564 | 0 | - | - | Restricted Stock Units | |
| Solventum Corp | Carlos Alban | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2025 | 3,564 | 3,564 | - | 0 | Common Stock | |
| Solventum Corp | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 3,403 | 3,403 | - | - | Restricted Stock Units | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 12,216 | 12,216 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 4,095 | 18,801 (0%) | 0% | 0 | Common Stock | |
| Solventum Corp | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 3,564 | 3,564 | - | - | Restricted Stock Units | |
| Solventum Corp | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2024 | 1,980 | 5,544 | - | - | Restricted Stock Units | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 13,774 | 13,774 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2023 | 4,648 | 14,706 (0%) | 0% | 0 | Common Stock | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2022 | 30,160 | 30,160 | - | - | Stock Option (Right to Buy) | |
| SpringWorks Therapeutics Inc | Carlos Alban | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jul 2022 | 10,058 | 10,058 (0%) | 0% | 0 | Common Stock | |
| Abbvie Inc | Carlos Alban | Vice Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.88 per share. | 16 Nov 2020 | 115,830 | 230,729 (0%) | 0% | 35.9 | 4,155,980 | Common Stock, $0.01 par value |
| Abbvie Inc | Carlos Alban | Vice Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2020 | 115,830 | 0 | - | - | Option(Right to buy) | |
| Abbvie Inc | Carlos Alban | Vice Chairman | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 16 Nov 2020 | 115,830 | 114,899 (0%) | 0% | 100 | 11,583,000 | Common Stock, $0.01 par value |
| Abbvie Inc | Carlos Alban | Vice Chairman | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 07 Jul 2020 | 30,325 | 137,899 (0%) | 0% | 100.0 | 3,032,555 | Common Stock, $0.01 par value |
| Abbvie Inc | Carlos Alban | Vice Chairman | Sale of securities on an exchange or to another person at price $ 100.00 per share. | 07 Jul 2020 | 23,000 | 114,899 (0%) | 0% | 100 | 2,300,000 | Common Stock, $0.01 par value |